Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10 ... insulin use, or molecular structure of GLP-1 agonist ...

Structure Therapeutics ... going to combine this GLP-1R agonist with other drugs from its pipeline like an APJR agonist ANPA-0073, GIPR selective agonist and amylin receptor agonist.

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

US biotech Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a strategic in-licensing agreement with China’s ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels. Further research led to the creation of a stabilized GLP-1RA called semaglutide, the active ...

These important receptors regulate numerous and diverse ... In order to compete at the "sharp end" of the GLP-1 business, Structure will also need good management, and their CEO, Raymond Stephens ...

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...